Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 23.12m |
Free float | 14.99m |
P/E (TTM) | -- |
Market cap | 1.23bn PLN |
EPS (TTM) | -4.15 PLN |
Data delayed at least 15 minutes.
More ▼
Press releases
- Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
- Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
- Ryvu Therapeutics Announces Dosing of the First Patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
- Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update